ライフサイエンスコーパス: therapeutic

1 tive inhibitor of MEK1/2 for use as a cancer therapeutic.

2 perty relevant for its developability into a therapeutic.

3 application of measles virus as an oncolytic therapeutic.

4 the development of protein-based anticancer therapeutics.

5 avenues for selective and prolonged cardiac therapeutics.

6 portant challenges faced by current anti-AXL therapeutics.

7 new opportunities to impact diagnostics and therapeutics.

8 health monitors and advanced, bioelectronic therapeutics.

9 ion proteinopathies and advancing anti-prion therapeutics.

10 hysiologic understanding and fostering novel therapeutics.

11 action inhibitors as a novel class of cancer therapeutics.

12 ound for the development of novel anticancer therapeutics.

13 robust platform to produce highly functional therapeutics.

14 e important clinical consequences, including therapeutics.

15 an essential obstacle to brain transport of therapeutics.

16 r biological processes, and discovery of new therapeutics.

17 development of Sirt6 activators as tools and therapeutics.

18 in cell signaling, medical diagnostics, and therapeutics.

19 en developing clinically relevant bispecific therapeutics.

20 h the intent to rapidly develop vaccines and therapeutics.

21 tial for development as cocaine use disorder therapeutics.

22 ptor coregulatory molecule GITR exert potent therapeutic activities in preclinical tumor models.

23 of fatty acid and a substantial loss in the therapeutic activity.

24 Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild,

25 bitors could lead to promising host-directed therapeutic adjuvants for tuberculosis treatment.

26 r related small molecules may be explored as therapeutic adjuvants to improve disease outcomes during

27 nds that alter neuronal function can lead to therapeutic advances that ameliorate age-related neurode

28 Ironically, despite tremendous therapeutic advances, there is an increasing treatment g

29 Natural products have served as powerful therapeutics against pathogenic bacteria since the golde

30 f the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer.

31 hese findings establish 15D11 as a potential therapeutic agent for the prevention or treatment of bon

32 molecular-weight oligomers that can act as a therapeutic agent in vitro and in vivo.

33 domain inhibitors (BETi) represent promising therapeutic agents for metastatic melanoma, yet their me

34 esidual disease, assess tumour resistance to therapeutic agents, and potentially screen individuals f

35 f biliary disorders and the testing of novel therapeutic agents.

36 ce for its application in the development of therapeutics aimed at correcting the conformation of pol

37 revascularization procedures, there are few therapeutic alternatives, leading to amputations and dea

38 The huntingtin aggregation pathways are of therapeutic and diagnostic interest, but obtaining criti

39 Therapeutic and diagnostic multifunctional HNPs conjugat

40 Antimalarial compounds with dual therapeutic and transmission-blocking activity are desir

41 N9 vaccine immunogens, a promising candidate therapeutic, and a tool for exploring mechanisms of viru

42 ecular component of the eye's vitreous, with therapeutic antibodies and proteins.

43 cted intracellular space to the potential of therapeutic antibodies.

44 vo cardiac function of IF1 and the potential therapeutic application targeting IF1 remain obscure.

45 siRNA carriers for in vivo purposes towards therapeutic applications.

46 s to generate a scalable source of cells for therapeutic applications.

47 i-inflammatory proteins for potential future therapeutic applications.

48 strong, specific binding for engineering and therapeutic applications.

49 est that CDK6 antagonists may be a promising therapeutic approach for Hh-associated medulloblastoma i

50 rs with STAT3 signaling inhibitor might be a therapeutic approach for the treatment of GBM.

51 enous spatiotemporal dynamics is a potential therapeutic approach for treating stress-induced behavio

52 K5-mediated effects may offer potential as a therapeutic approach in AD.

53 Syk inhibition has been proposed as a new therapeutic approach in asthma.

54 A promising therapeutic approach may be classical pathway (CP) inhib

55 with this Notch-dependent crosstalk may be a therapeutic approach to block metastasis.

56 g enzymes has been considered to be a viable therapeutic approach to enhance their antinociceptive an

57 rection of MCP1 deficiency may thus be a new therapeutic approach to SMA.SIGNIFICANCE STATEMENT Spina

58 ophosphate (cAMP) has emerged as a promising therapeutic approach to treat cognitive deficits.

59 oblast formation in vivo, suggesting a novel therapeutic approach with p38 inhibitors for future clin

60 target apoptotic pathways may be a promising therapeutic approach.

61 e rationale of targeting BCL6 as a potential therapeutic approach.

62 inhibitors is probably inevitable, and novel therapeutic approaches are needed to target dormant tumo

63 ns for organismal health and could offer new therapeutic approaches for neurodegenerative diseases an

64 may offer a novel opportunity for designing therapeutic approaches for these diseases.

65 These data may provide important guidance to therapeutic approaches in the HIV cure agenda.

66 ocytes and endothelial cells may lead to new therapeutic approaches to improve blood vessel regenerat

67 athogenic pathways in AKI may identify novel therapeutic approaches.

68 model has been widely used for testing novel therapeutic approaches.

69 that result in LSC survival and develop new therapeutic approaches.

70 unction and have potential as nervous system therapeutics as well.

71 VID with immune dysregulation will offer new therapeutic avenues for this subgroup.

72 ctors and high throughput screening of novel therapeutics becoming the mainstay of treatment.

73 ociated with improved survival and may offer therapeutic benefit among carefully selected patients.

74 that suppressing the PAK pathway might be of therapeutic benefit in this type of melanoma.

75 e mechanism whereby DcpS inhibition leads to therapeutic benefit is unclear.

76 pport normal balance behaviors, suggesting a therapeutic benefit to balance with ASO-29 treatment at

77 cing Nemo through gene therapy might provide therapeutic benefits.

78 erfacing activities of natural stem cells in therapeutic cardiac regeneration.

79 ral and electroporation methods for creating therapeutic cell-based products are complex and expensiv

80 complex protocols currently used to program therapeutic cells, so our methods will likely facilitate

81 e greatly improved knowledge of the disease, therapeutic choices are insufficient to prevent some of

82 sented, aiming at facilitating the p53-based therapeutic choices.

83 In this study, we deliver therapeutic compounds to neutrophils using biocompatible

84 Tumor hypoxia is a therapeutic concern since it can reduce the effectivenes

85 BMR prognostic score could be used to inform therapeutic decisions in clinical practice and for the d

86 Most satiety-inducing obesity therapeutics, despite modest efficacy, have safety conce

87 nvolving FcRn and may facilitate vaccine and therapeutic development for other ocular surface disease

88 Use of this end point may expedite therapeutic development with the intent of bringing nove

89 otential for a wide range of applications in therapeutic development, and fundamental understanding o

90 tant for further informing Ebola vaccine and therapeutic development.

91 form for studying RNA in mammalian cells and therapeutic development.

92 tment mediators that will facilitate further therapeutic development.

93 SMA therapeutics development efforts have focused on identif

94 an updated vision of current and foreseeable therapeutic developments in chronic hepatitis B.

95 mplement traditional means of diagnostic and therapeutic discovery.

96 biosensors can be used to reveal potentially therapeutic dopamine D1 receptor and adenosine A2A recep

97 h the use of dosing software supplemented by therapeutic drug monitoring data should be embedded into

98 the impact of selected ferrociphenols as new therapeutic drugs for such cancers.

99 nt creates a physiological barrier for using therapeutic drugs in the stomach.

100 tually for designing new molecules toward AD therapeutic drugs.

101 BCM-PTX injection further improved the tumor therapeutic effect and elongated the survival time of th

102 Correlation between therapeutic effect and thermal parameters was confirmed

103 The therapeutic effect of OEPCs is improved in vivo by inhib

104 enchymal stem cell (MSC) studies assume that therapeutic effects accrue from local myocardial effects

105 The potential therapeutic effects of agonistic analogs of growth hormo

106 f this study is to investigate the potential therapeutic effects of cortistatin in two well-establish

107 xorubicin-loaded (D)CDX-RBCNPs have superior therapeutic efficacy and markedly reduced toxicity as co

108 Therapeutic efficacy and tumor necrosis area were compar

109 -PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.

110 These results demonstrate clinical therapeutic efficacy from gene therapy for ADA-deficient

111 We show that ENb-TRAIL has therapeutic efficacy in tumor cells from different cance

112 ing OT under opioid antagonism may boost the therapeutic efficacy of OT for enhancing social cognitio

113 affinity to human receptors and enhance its therapeutic efficacy.

114 gonist immunotherapies resulting in superior therapeutic efficacy.MEK inhibition in breast cancer is

115 rhagic fever outbreaks for which no approved therapeutic exists.

116 zymes were administered in a prophylactic or therapeutic fashion, autoimmune inflammation was markedl

117 ge mass spectrometry (HDX-MS) in the protein therapeutic field is undisputed; however, its applicabil

118 scyllo-Inositol (SI) is a potential therapeutic for AD by directly interacting with the Abet

119 ld facilitate improvement of diagnostics and therapeutics for affected patients with bleeding disorde

120 ands have commonly been targeted by antibody therapeutics for cancers and other diseases.

121 or the stratification and development of new therapeutics for depression, and the next steps that nee

122 emicals have gained attention as alternative therapeutics for managing cardiovascular diseases.

123 mbination cancer therapy using nucleic acids therapeutics for successful clinical translation.

124 nd introduce NMDA-R antagonists as potential therapeutics for this fatal disease.

125 Thus, ROCK inhibitors represent potential therapeutics for VHL-deficient CC-RCC.

126 ancer and inflammation management, including therapeutics, imaging and theranostics.

127 y role for BCAT1 in macrophage function with therapeutic implications for inflammatory conditions.

128 dissemination, with potential prognostic and therapeutic implications for metastasis by cancers that

129 mon or rare genetic variation with potential therapeutic implications for T2D, we analyzed and replic

130 The therapeutic implications of these natural, remote-loaded

131 ementation with precursors such as NR may be therapeutic in settings of acute liver injury.

132 barrier and drive widespread distribution of therapeutics in brain parenchyma away from the point of

133 iate potential for serving as biomarkers and therapeutics in dermatology over the next decade.

134 ribed cardiovascular medicines in China, its therapeutic indications and mechanisms remain partially

135 to induce cholinergic AEs and convulsion at therapeutic indices similar to previous compounds with m

136 e density may influence clinical response to therapeutic inhibition of tonic BCR signaling in DLBCL.

137 plicability of RT-QuIC to identify potential therapeutic inhibitors of prion conversion.

138 ediated translation strategy is a target for therapeutic intervention against this viral disease.

139 generation and this offers opportunities for therapeutic intervention aimed at the prevention of neur

140 of B cell homeostasis, and it is a target of therapeutic intervention in autoimmune diseases and lymp

141 Our analysis demonstrates that successful therapeutic intervention will be highly dependent on the

142 des by identifying key strategies for future therapeutic intervention.

143 e prevention, pathogenesis, progression, and therapeutic intervention.

144 ggest that these pathways can be studied for therapeutic intervention.

145 lective options for diagnosis as well as for therapeutic intervention.

146 ffect, representing an attractive target for therapeutic intervention.

147 ession, and provide avenues for personalized therapeutic interventions and precision medicine for opt

148 ore these recently-identified mechanisms and therapeutic interventions are being tested, which hopefu

149 ath pathways will help in the development of therapeutic interventions in intestinal pathologies.

150 anolol may be a useful adjunct to behavioral therapeutic interventions in recently traumatized indivi

151 efore be relevant for diagnostic purposes or therapeutic interventions of allergic diseases.

152 Studies on underlying causes and therapeutic interventions seem warranted.

153 These observations suggest that therapeutic interventions should target subjective alcoh

154 n factors and provide structural insight for therapeutic interventions targeting AP-1 proteins.

155 provide unique insight to exploit for novel therapeutic interventions.

156 he activity of the "drug-free macromolecular therapeutics" is based on the biorecognition of compleme

157 e, as its clinical evaluation may change the therapeutic landscape.

158 and NO donor functionalities that provide a therapeutic level of NO necessary to promote angiogenesi

159 ng MN arrays to deliver GEN transdermally at therapeutic levels in vivo.

160 sistant infecting strains and to help inform therapeutic management.

161 sus opinion recommends surgical excision for therapeutic management.

162 The available therapeutic measures aimed at preventing the risk for in

163 present the first, to our knowledge, in vivo therapeutic micromotors application for active drug deli

164 therapy, and surgical intervention if other therapeutic modalities fail to prevent progression.

165 Combining ALK inhibition with other novel therapeutic modalities should prove even more effective.

166 be safely used as an antidote during adverse therapeutic modulation of hemostasis.

167 tance in Type-2 diabetes, in which the unmet therapeutic need remains substantial.

168 portance of achieving widespread delivery of therapeutic nucleic acids within brain tumors and provid

169 els that can accurately predict the delay to therapeutic onset.

170 thylation patterns that may allow for future therapeutic opportunities.

171 CT-P10 might represent a new therapeutic option for advanced-stage follicular lymphom

172 eplacement (TMVR) has emerged as a potential therapeutic option for the treatment of severe MR.

173 or drug delivery and new classifications and therapeutic options for various forms of hydrocephalus a

174 would have distinct advantages over current therapeutic options, yet experimental vaccines have not

175 rgy is common, life-threatening, and without therapeutic options.

176 e knowledge gaps and inadequacies of current therapeutic options.

177 te the metastatic cascade and the paucity of therapeutic options.

178 tumour suppressors with drug targets informs therapeutic options.

179 eatments that can enhance or replace current therapeutic options.

180 r with a heterogeneous phenotype and limited therapeutic options.

181 wth, progressive loss of vision, and limited therapeutic options.

182 of senescence and target of anti-senescence therapeutics, or senolytics.

183 most judicious to achieve a highly effective therapeutic outcome.

184 that altering tumor metabolism could change therapeutic outcome.

185 bined with 1% ALN gel results in significant therapeutic outcomes when compared with PRF and access t

186 Investigating therapeutic "outliers" that show exceptional responses t

187 ty disorders and suggest a potentially wider therapeutic overlap between AEA and 2-AG augmentation ap

188 rate of corneal perforation or the need for therapeutic penetrating keratoplasty.

189 d's possible active ingredients but also its therapeutic, pharmacological and chemical properties, th

190 The results changed the therapeutic plan in 84 patients (80.8%).

191 growth control and may also find utility in therapeutic planning to avoid postsurgery metastatic acc

192 nity for integrin VLA-3, which reveals novel therapeutic possibilities.

193 ombinant reoviruses as candidates to enhance therapeutic potency.

194 of PTX3 in response to GroEL, which thus has therapeutic potential for clearance of bacterial infecti

195 abotropic glutamate receptor 5 (mGluR5) have therapeutic potential in autism spectrum disorders (ASD)

196 ted in cancer, tankyrase inhibitors may have therapeutic potential in targeting this pathway.

197 Signaling through cGMP has therapeutic potential in the colon, where it has been im

198 These results suggest a therapeutic potential of alpha7nAChR agonists in early r

199 rmone glucagon-like peptide-1 highlights the therapeutic potential of gut-derived signals acting via

200 oratory study in human cirrhosis suggest the therapeutic potential of selective renal vasodilation us

201 ical trial is in progress to investigate the therapeutic potential of SGN-CD19B in relapsed/refractor

202 The present review highlights the therapeutic potential of targeting B7-H4.

203 groundwork for future studies assessing the therapeutic potential of targeting Nck in aggressive can

204 t-Ras-HO-1 axis; and it can have significant therapeutic potential to prevent post-transplantation ca

205 2-mediated protection from AKI, bears strong therapeutic potential.

206 oll-like receptors (TLRs) may offer superior therapeutic profiles than that of single TLR activation.

207 life is an important issue in developing new therapeutic proteins and expanding applications of exist

208 teins and expanding applications of existing therapeutic proteins.

209 g consequences on the safety and efficacy of therapeutic proteins.

210 ding of ABMR and be useful for diagnostic or therapeutic purposes.

211 -escalation has the potential to improve the therapeutic ratio and long-term function for these patie

212 +) cells in inflamed islets and suggest that therapeutic regulatory T cells directly or indirectly re

213 racterize V-ATPase and to fully evaluate the therapeutic relevance of V-ATPase in human diseases.

214 tional wtp53 inactivation, which might be of therapeutic relevance.

215 Tumor development and therapeutic resistance are linked with tumor-associated

216 S6), are important drivers of metastasis and therapeutic resistance in human cancers.

217 cy in treating human metastatic cancers, but therapeutic resistance is a practical limitation and mos

218 th targeted BRAF inhibitors, we hypothesized therapeutic response is related to tumor metabolic pheno

219 s condition with varying natural history and therapeutic response.

220 in serum calprotectin levels were linked to therapeutic responses to antibiotics.

221 soforms thus represent potential targets for therapeutic RNA interference (RNAi) in both early and la

222 hether alternative anticoagulants may have a therapeutic role.

223 our separate report, may help to expand the therapeutic spectrum of HU to additional pathological co

224 Thus more tailored prevention and therapeutic strategies are still lacking.

225 types and genotypes in designing nonsurgical therapeutic strategies for uterine leiomyoma.

226 erence approaches are emerging as attractive therapeutic strategies in neurological diseases.

227 ance of T-cell homeostasis and outline novel therapeutic strategies tailored to manipulate cell death

228 Therapeutic strategies that combine MEK inhibitors with

229 y synaptic dysfunction would be an effective therapeutic strategy for AD.

230 ion toxin proteins could form the basis of a therapeutic strategy for eliminating latently infected c

231 These results reveal a new therapeutic strategy for GCD2; this method may also be a

232 -associated DNA repair may represent a novel therapeutic strategy for gliomas.

233 NRP1 or its NCD interactors may be a useful therapeutic strategy in neovascular disease to reduce VE

234 e growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimm

235 ncement of NAMPT activity as a promising new therapeutic strategy to protect against anticancer drug-

236 ial to activate latent plasticity as a novel therapeutic strategy to restore synaptic strength.

237 ion will be highly dependent on the specific therapeutic target and the stage of PVR.

238 t Ep3 receptor activation may be a promising therapeutic target for acute MI.

239 tate and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.

240 ogenesis and point to its potential as a new therapeutic target for angiogenesis-related diseases.

241 o, suggesting that DGKalpha is an attractive therapeutic target for DN.

242 tion in patients with EoE and is a potential therapeutic target for EoE and related eosinophilic and

243 ys and suggest that Gab2 might be a powerful therapeutic target for HCC.

244 r metastasis and suggest PLD2 as a potential therapeutic target for metastatic breast cancer.

245 lopment and suggest that NOX4 is a potential therapeutic target for PDAC.

246 ical role after SCI, and may provide a novel therapeutic target for SCI.

247 aintenance of TCL and represents a potential therapeutic target for TCL.

248 galanin-opioid interactions and offers a new therapeutic target for the treatment of opioid use disor

249 CD4 T cells, highlighting its potential as a therapeutic target for treating autoimmune diseases.

250 ional signaling pathway offers an innovative therapeutic target for treating hypoxic-ischemic human d

251 Sebaceous gland ACC represents an attractive therapeutic target given its central role in formation o

252 stic biological research, disease modelling, therapeutic target identification, drug testing and rege

253 t-versus-leukemia effects, unveiling a novel therapeutic target in aGVHD treatment or prevention.

254 This interaction may represent a therapeutic target in cancers that express ephrinB1.

255 ta1-JAG1-NOTCH signaling axis as a candidate therapeutic target in glioma patients.

256 y express AR, emphasizing its potential as a therapeutic target in patients with CRPC.

257 ay represent a key modifiable risk factor or therapeutic target in the preclinical phases of AD.

258 artilaginous tissue and serve as a potential therapeutic target in the treatment of OA.

259 ages and indicates a potential host-directed therapeutic target to limit the damaging inflammation as

260 Our findings highlight TBX2 as a novel therapeutic target upstream of WNT3A, where WNT3A antago

261 Our data identified Runx1 as a novel therapeutic target with translational potential to count

262 BRAF-V600E also represents a new therapeutic target.

263 ement, we serendipitously identified a novel therapeutic target: DAT oligomer complexes.

264 fferences may have clinical significance, as therapeutic targeting of a signaling pathway such as NG2

265 ns for UNO peptide in diagnostic imaging and therapeutic targeting of MEMs in solid tumors.

266 at can be targeted for mechanistic study and therapeutic targeting of peanut allergy.

267 traditionally been successfully treated with therapeutics targeting the IL-1 pathway; however, there

268 TGFbeta1 in fibroblasts could be attractive therapeutic targets and lack upstream toxicity.

269 r progression in smokers, representing novel therapeutic targets for breast cancer patients who smoke

270 ds such as allopregnanolone may be potential therapeutic targets for depression and anxiety in tradit

271 d in vascular tissues and identify potential therapeutic targets for hypertension.

272 N-terminal kinase and NF-kappaB as potential therapeutic targets for prevention of squamous cell carc

273 bolic pathways, which may identify potential therapeutic targets for the disease.

274 Several of these processes may be potential therapeutic targets for the prevention and treatment of

275 ption and AD, and therefore we present novel therapeutic targets for this disease.

276 Her2 (ERBB2) is one of the most established therapeutic targets in breast and gastric cancer but age

277 eins, which present promising diagnostic and therapeutic targets in PDAC.

278 n and prioritization of chemically tractable therapeutic targets is a significant challenge in the di

279 We discuss the two major candidate therapeutic targets to lower amyloid-beta in a preventiv

280 sors and increasingly considered as putative therapeutic targets.

281 provides potential diagnostic biomarkers and therapeutic targets.

282 nic mechanisms hampers the identification of therapeutic targets.

283 ify gene expression signatures and candidate therapeutics that could improve the treatment of metasta

284 le different physical imaging modalities and therapeutic/theranostic capabilities), their key propert

285 We evaluate the major challenges in choosing therapeutics to prevent congenital ZIKV disease and cond

286 t may serve as a new approach in our growing therapeutic toolbox.

287 Chk1 inhibitors may be a potentially useful therapeutic treatment for patients whose tumours contain

288 mportant insights into diabetes research and therapeutic treatments.

289 hese findings strongly support the potential therapeutic use of this antibody in the treatment of sys

290 all molecules and biologics that could be of therapeutic use.

291 fe and effective treatments, a preventive or therapeutic vaccine, and specific and sensitive tests an

292 implications for the potential success of a therapeutic vaccine.

293 s required for antilatency strategies and/or therapeutic vaccines to boost functional antibodies and

294 rafish model for screening of molecules with therapeutic value against this toxic neuropathy.

295 dogenously generated bioregulator and/or has therapeutic value.

296 ther provides a potential approach to create therapeutic vectors that can be photoactivated in vivo w

297 virulence determinants or the evaluation of therapeutics, we infected them with a green fluorescent

298 To facilitate development of topical therapeutics, we need an efficient model for assessing d

299 in tumour development, and indicate a viable therapeutic window for LGK974 treatment of RSPO-fusion c

300 the respiratory suppression/antinociception therapeutic window in a series of compounds spanning a w